Jeffrey H Newcorn Selected Research

Guanfacine (Tenex)

1/2020	Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
1/2019	Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
10/2018	Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
1/2016	Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment.
1/2016	Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
11/2015	Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
3/2015	Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study.
10/2014	Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form.
9/2013	Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
6/2013	A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey H Newcorn Research Topics

Disease

95	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 03/2022 - 04/2002
5	Substance-Related Disorders (Drug Abuse) 10/2018 - 11/2006
3	Oppositional Defiant Disorder 01/2020 - 03/2005
3	Mental Disorders (Mental Disorder) 02/2016 - 09/2007
2	Sleepiness 01/2019 - 10/2018
2	Disorders of Excessive Somnolence (Hypersomnia) 01/2019 - 10/2018
2	Antisocial Personality Disorder (Antisocial Personality) 12/2018 - 07/2006
2	Fatigue 01/2018 - 12/2012
2	Nausea 01/2018 - 12/2012
1	Cardiotoxicity 01/2021
1	Sluggish Cognitive Tempo 01/2021
1	Sleep Wake Disorders 01/2020
1	Narcolepsy 01/2020
1	Conduct Disorder (Conduct Disorders) 12/2018
1	Constipation 01/2018
1	Alcoholism (Alcohol Abuse) 08/2017
1	Mood Disorders (Mood Disorder) 02/2016
1	Hypertension (High Blood Pressure) 06/2014
1	Pre-Eclampsia (Preeclampsia) 06/2014
1	Headache (Headaches) 12/2012
1	Wounds and Injuries (Trauma) 10/2011
1	Bulimia Nervosa 04/2010
1	Autistic Disorder (Autism) 02/2010
1	Major Depressive Disorder (Major Depressive Disorders) 04/2004
1	Confusion (Bewilderment) 07/2002

Drug/Important Bio-Agent (IBA)

22	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 07/2017 - 07/2002
19	Methylphenidate (Ritalin)FDA LinkGeneric 03/2022 - 07/2002
16	Pemetrexed (MTA)FDA Link 02/2022 - 05/2002
11	Guanfacine (Tenex)FDA LinkGeneric 01/2020 - 01/2003
5	Amphetamine (Amfetamine)FDA LinkGeneric 01/2019 - 04/2002
5	Pharmaceutical PreparationsIBA 10/2018 - 07/2002
4	Lisdexamfetamine Dimesylate FDA Link 01/2021 - 11/2017
4	Biological ProductsIBA 01/2020 - 11/2006
4	Dopamine (Intropin)FDA LinkGeneric 07/2014 - 09/2009
3	metadoxineIBA 01/2020 - 12/2012
3	Serotonin (5 Hydroxytryptamine)IBA 02/2010 - 05/2002
2	ViloxazineIBA 01/2021 - 01/2020
2	Hypnotics and Sedatives (Sedatives)IBA 01/2019 - 10/2018
2	Hydrocortisone (Cortisol)FDA LinkGeneric 12/2018 - 10/2011
2	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2015 - 05/2006
2	Adrenergic Receptors (Adrenergic Receptor)IBA 03/2013 - 08/2009
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2013 - 11/2010
2	Dexmethylphenidate Hydrochloride FDA LinkGeneric 12/2011 - 08/2007
2	SaltsIBA 12/2011 - 04/2002
1	AmphetaminesIBA 10/2021
1	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA 01/2021
1	Antidepressive Agents (Antidepressants)IBA 01/2021
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 01/2021
1	Capsules (Microcapsules)IBA 01/2020
1	IronIBA 01/2020
1	4-aminospiroperidolIBA 12/2018
1	Mazindol (Mazanor)FDA Link 01/2018
1	Adenosine Monophosphate (AMP)IBA 08/2017
1	TabletsIBA 08/2017
1	Biomarkers (Surrogate Marker)IBA 07/2017
1	Dopamine Agents (Dopaminergic Agents)IBA 07/2017
1	Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)IBA 10/2016
1	Excipients (Suspending Agents)IBA 02/2016
1	Antipsychotic Agents (Antipsychotics)IBA 02/2016
1	trans-sodium crocetinate (crocetin)IBA 12/2015
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 03/2015
1	Dopamine Receptors (Dopamine Receptor)IBA 07/2014
1	Proteins (Proteins, Gene)FDA Link 06/2014
1	TEMPOIBA 09/2013
1	Clonidine (ST 155)FDA LinkGeneric 06/2013
1	Delayed-Action PreparationsIBA 06/2013
1	Cocaine (Cocaine HCl)IBA 01/2013
1	Aligeron (AS 2)IBA 12/2012
1	Therapeutic UsesIBA 09/2012
1	galantide (M 15)IBA 10/2011
1	3' Untranslated Regions (3' UTR)IBA 11/2010
1	Central Nervous System StimulantsIBA 01/2010
1	LigandsIBA 09/2009
1	4,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA 03/2009
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 06/2008
1	Controlled SubstancesIBA 08/2007
1	FenfluramineIBA 05/2007
1	Fluoxetine (Prozac)FDA LinkGeneric 09/2005
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 04/2004
1	alpha-2 Adrenergic ReceptorsIBA 01/2003
1	Growth Hormone (Somatotropin)IBA 01/2003
1	Tamoxifen FDA LinkGeneric 07/2002
1	ProlactinIBA 05/2002

Therapy/Procedure

21	Combined Modality Therapy 02/2022 - 05/2002
6	Drug Therapy (Chemotherapy) 01/2022 - 07/2005
4	Therapeutics 01/2021 - 07/2002
1	Treatment Delay 01/2021
1	Off-Label Use 01/2020
1	Ambulatory Care (Outpatient Care) 09/2011
1	Aftercare (After-Treatment) 05/2009
1	Oral Administration 01/2003